Home LiteratureArticle Details
PMID: 7666524 Published · ppublish English Comparative Study Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1.

Journal of virology ·Vol. 69 ·No. 10 ·1995-10-00 ·Pages 6239-48

Girard M, Meignier B, Barré-Sinoussi F, Kieny MP, Matthews T, Muchmore E, Nara PL, Wei Q, Rimsky L, Weinhold K

Abstract

The extraordinary genetic diversity of human immunodeficiency virus type 1 (HIV-1) is a major problem to overcome in the development of an effective vaccine. In the most reliable animal model of HIV-1 infection, chimpanzees were immunized with various combinations of HIV-1 antigens, which were derived primarily from the surface glycoprotein, gp160, of HIV-1 strains LAI and MN. The immunogens also included a live recombinant canarypox virus expressing a gp160-MN protein. In one experiment, two chimpanzees were immunized multiple times; one animal received antigens derived only from HIV-1LAI, and the second animal received antigens from both HIV-1LAI and HIV-1MN. In another experiment, four chimpanzees were immunized in parallel a total of five times over 18 months; two animals received purified gp160 and V3-MN peptides, whereas the other two animals received the recombinant canarypox virus and gp160. At 3 months after the final booster, all immunized and naive control chimpanzees were challenged by intravenous inoculation of HIV-1SF2; therefore, the study represented an intrasubtype B heterologous virus challenge. Virologic and serologic follow-up showed that the controls and the two chimpanzees immunized with the live recombinant canarypox virus became infected, whereas the other animals that were immunized with gp160 and V3-MN peptides were protected from infection. Evaluation of both cellular and humoral HIV-specific immune responses at the time of infectious HIV-1 challenge identified the following as possible correlates of protection: antibody titers to the V3 loop of MN and neutralizing antibody titers to HIV-1MN or HIV-1LAI, but not to HIV-1SF2. The results of this study indicate that vaccine-mediated protection against intravenous infection with heterologous HIV-1 strains of the same subtype is possible with some immunogens.

MeSH Terms
AIDS Vaccines/immunology Acquired Immunodeficiency Syndrome/blood,immunology,virology Animals Base Sequence DNA Primers DNA, Viral/analysis,genetics Giant Cells HIV Antibodies/blood HIV Antigens/immunology HIV-1/classification,genetics,immunology Immunoblotting Male Molecular Sequence Data Pan troglodytes Polymerase Chain Reaction/methods Species Specificity Time Factors
Chemicals
AIDS Vaccines DNA Primers DNA, Viral HIV Antibodies HIV Antigens
Authors & Affiliations
10 authors, click to expand affiliations / ORCID
Girard M
Institut Pasteur, Paris, France.
Meignier B
Barré-Sinoussi F
Kieny M P
Matthews T
Muchmore E
Nara P L
Wei Q
Rimsky L
Weinhold K
References (61)
61 references, click to expand
  1. Isolation of recombinant partial gag gene product p18 (HIV-1Bru) from Escherichia coli.
    J Chromatogr. 1989 Aug 4;476:99-112 PMID: 2674178
  2. A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA.
    AIDS Res Hum Retroviruses. 1995 Mar;11(3):373-81 PMID: 7598771
  3. Human immunodeficiency virus-infected individuals contain provirus in small numbers of peripheral mononuclear cells and at low copy numbers.
    J Virol. 1990 Feb;64(2):864-72 PMID: 2296085
  4. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.
    Nature. 1990 Jun 14;345(6276):622-5 PMID: 2190095
  5. Induction of CD4+ human cytolytic T cells specific for HIV-infected cells by a gp160 subunit vaccine.
    Science. 1990 Jun 8;248(4960):1234-7 PMID: 2190315
  6. Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees.
    J Virol. 1990 Aug;64(8):3779-91 PMID: 2370681
  7. Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant.
    Science. 1990 Aug 24;249(4971):932-5 PMID: 2392685
  8. Human monoclonal antibody that recognizes the V3 region of human immunodeficiency virus gp120 and neutralizes the human T-lymphotropic virus type IIIMN strain.
    Proc Natl Acad Sci U S A. 1990 Nov;87(21):8597-601 PMID: 1700435
  9. Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody.
    J Virol. 1991 Jan;65(1):489-93 PMID: 1702163
  10. Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus.
    Proc Natl Acad Sci U S A. 1991 Jan 15;88(2):542-6 PMID: 1988952
  11. Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1.
    Science. 1990 Dec 14;250(4987):1590-3 PMID: 1703322
  12. Sequential immunizations with rgp120s from independent isolates of human immunodeficiency virus type 1 induce the preferential expansion of broadly crossreactive B cells.
    J Exp Med. 1991 Apr 1;173(4):881-7 PMID: 2007856
  13. Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS.
    Science. 1984 Aug 24;225(4664):840-2 PMID: 6206563
  14. Persistent infection of chimpanzees with human T-lymphotropic virus type III/lymphadenopathy-associated virus: a potential model for acquired immunodeficiency syndrome.
    J Virol. 1986 Apr;58(1):116-24 PMID: 3005641
  15. Variable and conserved neutralization antigens of human immunodeficiency virus.
    Nature. 1986 Dec 11-17;324(6097):572-5 PMID: 2431324
  16. An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity.
    J Immunol Methods. 1986 Dec 24;95(2):157-68 PMID: 3540125
  17. Proliferative and cytotoxic T cells to AIDS virus glycoproteins in chimpanzees immunized with a recombinant vaccinia virus expressing AIDS virus envelope glycoproteins.
    J Immunol. 1987 Aug 15;139(4):988-90 PMID: 3497202
  18. Effect of immunization with a vaccinia-HIV env recombinant on HIV infection of chimpanzees.
    Nature. 1987 Aug 20-26;328(6132):721-3 PMID: 3475581
  19. HIV F/3' orf encodes a phosphorylated GTP-binding protein resembling an oncogene product.
    Nature. 1987 Nov 19-25;330(6145):266-9 PMID: 3118220
  20. Superinfection of a chimpanzee with a second strain of human immunodeficiency virus.
    J Virol. 1987 Dec;61(12):4026-9 PMID: 2446009
  21. Simple, rapid, quantitative, syncytium-forming microassay for the detection of human immunodeficiency virus neutralizing antibody.
    AIDS Res Hum Retroviruses. 1987 Fall;3(3):283-302 PMID: 3481271
  22. Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides.
    Proc Natl Acad Sci U S A. 1988 Mar;85(6):1932-6 PMID: 2450351
  23. Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120.
    Proc Natl Acad Sci U S A. 1988 May;85(9):3198-202 PMID: 2452447
  24. Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope.
    J Virol. 1988 Jun;62(6):2107-14 PMID: 2452899
  25. Neutralization of diverse HIV-1 strains by monoclonal antibodies raised against a gp41 synthetic peptide.
    Virology. 1988 Jul;165(1):209-15 PMID: 2838959
  26. Characteristics of a neutralizing monoclonal antibody to the HIV envelope glycoprotein.
    AIDS Res Hum Retroviruses. 1988 Jun;4(3):187-97 PMID: 2456088
  27. Improved antigenicity of the HIV env protein by cleavage site removal.
    Protein Eng. 1988 Sep;2(3):219-25 PMID: 3237686
  28. HIV infection of chimpanzees as a model for testing chemotherapeutics.
    Intervirology. 1989;30 Suppl 1:51-8 PMID: 2708009
  29. Long-term observation of baboons, rhesus monkeys, and chimpanzees inoculated with HIV and given periodic immunosuppressive treatment.
    AIDS Res Hum Retroviruses. 1989 Apr;5(2):233-45 PMID: 2713168
  30. Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.
    Proc Natl Acad Sci U S A. 1989 Sep;86(17):6768-72 PMID: 2771954
  31. Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein.
    Proc Natl Acad Sci U S A. 1991 Apr 15;88(8):3238-42 PMID: 2014246
  32. Antibody-dependent cellular cytotoxicity against HIV-1 in sera of immunized chimpanzees.
    AIDS. 1991 Feb;5(2):169-76 PMID: 2031689
  33. Neutralization of HIV-1: a paradox of humoral proportions.
    FASEB J. 1991 Jul;5(10):2437-55 PMID: 1712328
  34. Immunization of chimpanzees with the HIV-1 glycoprotein gp160 induces long-lasting T-cell memory.
    AIDS Res Hum Retroviruses. 1991 May;7(5):485-93 PMID: 1714748
  35. Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to Gp120.
    Science. 1991 Oct 4;254(5028):105-8 PMID: 1718036
  36. Antibody responses of chimpanzees immunized with synthetic peptides corresponding to full-length V3 hypervariable loops of HIV-1 envelope glycoproteins.
    AIDS Res Hum Retroviruses. 1991 Oct;7(10):813-23 PMID: 1720628
  37. Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120.
    J Virol. 1992 Feb;66(2):848-56 PMID: 1370558
  38. Nonreplicating viral vectors as potential vaccines: recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins.
    Virology. 1992 Mar;187(1):321-8 PMID: 1736535
  39. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody.
    Nature. 1992 Feb 20;355(6362):728-30 PMID: 1741059
  40. Potential use of non-replicating vectors as recombinant vaccines.
    Vaccine. 1992;10(1):8-9 PMID: 1311489
  41. Induction of broadly cross-reactive cytotoxic T cells recognizing an HIV-1 envelope determinant.
    Science. 1992 Jan 17;255(5042):333-6 PMID: 1372448
  42. Immunisation with canarypox virus expressing rabies glycoprotein.
    Lancet. 1992 Jun 13;339(8807):1429-32 PMID: 1351126
  43. Vaccine protection of chimpanzees against challenge with HIV-1-infected peripheral blood mononuclear cells.
    Science. 1992 Jun 19;256(5064):1687-90 PMID: 1609280
  44. Two major groups of neutralizing anti-gp120 antibodies exist in HIV-infected individuals. Evidence for epitope diversity around the CD4 attachment site.
    J Immunol. 1992 Jul 15;149(2):649-54 PMID: 1378074
  45. Standardization of sensitive human immunodeficiency virus coculture procedures and establishment of a multicenter quality assurance program for the AIDS Clinical Trials Group. The NIH/NIAID/DAIDS/ACTG Virology Laboratories.
    J Clin Microbiol. 1992 Jul;30(7):1787-94 PMID: 1629336
  46. Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein.
    J Virol. 1992 Sep;66(9):5635-41 PMID: 1380099
  47. High-titer HIV-1 neutralizing antibody response of rhesus macaques to gp160 and env peptides.
    AIDS Res Hum Retroviruses. 1992 Jun;8(6):1117-23 PMID: 1503824
  48. Comparative clonal analysis of human immunodeficiency virus type 1 (HIV-1)-specific CD4+ and CD8+ cytolytic T lymphocytes isolated from seronegative humans immunized with candidate HIV-1 vaccines.
    J Exp Med. 1992 Dec 1;176(6):1531-42 PMID: 1460417
  49. Specific activation strategies for amplification of low CTL signals.
    AIDS Res Hum Retroviruses. 1992 Aug;8(8):1373 PMID: 1466958
  50. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network.
    J Infect Dis. 1993 Mar;167(3):533-7 PMID: 8095059
  51. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein.
    Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):1882-6 PMID: 8446603
  52. Vaccination to prevent persistent viral infection.
    J Virol. 1993 Jul;67(7):4372-8 PMID: 8510226
  53. Human CD4+ cytolytic T lymphocyte responses to a human immunodeficiency virus type 1 gp160 subunit vaccine.
    J Infect Dis. 1993 Jul;168(1):92-100 PMID: 8099941
  54. Human trials of experimental AIDS vaccines.
    AIDS. 1993;7 Suppl 1:S147-59 PMID: 8363779
  55. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1.
    J Virol. 1993 Nov;67(11):6642-7 PMID: 7692082
  56. Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group Network.
    J Infect Dis. 1993 Dec;168(6):1387-95 PMID: 8245523
  57. T-cell-mediated immunopathology versus direct cytolysis by virus: implications for HIV and AIDS.
    Immunol Today. 1994 Jun;15(6):262-8 PMID: 7915115
  58. Measuring vaccine-induced HIV neutralization: report of a workshop.
    AIDS Res Hum Retroviruses. 1994 Jun;10(6):645-8 PMID: 8074928
  59. Antibodies to the HIV-1 V3 loop in serum from infected persons contribute a major proportion of immune effector functions including complement activation, antibody binding, and neutralization.
    Virology. 1994 Nov 1;204(2):609-15 PMID: 7941328
  60. HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees.
    Vaccine. 1994 Sep;12(12):1141-8 PMID: 7998425
  61. Challenge of chimpanzees (Pan troglodytes) immunized with human immunodeficiency virus envelope glycoprotein gp120.
    J Virol. 1989 Dec;63(12):5046-53 PMID: 2555541
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
DOI
10.1128/JVI.69.10.6239-6248.1995
Published
1995-10-00
Pages
6239-48
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC189521
Subset
IM
External Links
PubMed source DOI: 10.1128/JVI.69.10.6239-6248.1995 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2